Celsion (CLSN) Sees Large Volume Increase

Celsion Co. (NASDAQ:CLSN) shares saw strong trading volume on Thursday . 2,914,104 shares traded hands during mid-day trading, an increase of 146% from the previous session’s volume of 1,185,848 shares.The stock last traded at $2.78 and had previously closed at $2.78.

A number of equities research analysts have recently issued reports on the company. ValuEngine lowered Celsion from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 15th. Maxim Group upgraded Celsion from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Wednesday, October 4th. Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Oppenheimer began coverage on Celsion in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.90.

The stock has a market capitalization of $44.65, a price-to-earnings ratio of -0.47 and a beta of 1.22.

An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC purchased a new stake in Celsion Co. (NASDAQ:CLSN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion as of its most recent filing with the Securities and Exchange Commission (SEC). 3.97% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Celsion (CLSN) Sees Large Volume Increase” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/01/04/celsion-clsn-sees-large-volume-increase.html.

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply